Study: Black women with breast cancer experience delayed, longer treatment than whites

September 21, 2020

CHAPEL HILL, N.C.--One in seven black women with breast cancer had delays in starting treatment, and black women also had extended duration of treatment, according to a study led by UNC Lineberger Comprehensive Cancer Center researchers.

In the journal Cancer, Melissa Troester, PhD, Marc Emerson, PhD, and their colleagues report that Black women were more likely than white women (13.4% vs. 7.9%) to have the start of the care delayed by at least 60 days after diagnosis. Black women were also more likely to have longer duration of treatment, as were women under the age of 50 of all races.

The study assessed a variety of patient-reported factors for their impact on delaying start or prolonging duration. While access to care, tumor status and socioeconomic status did affect treatment start times, these factors had greater impact on the length of care. It was also notable that socioeconomic status was not as strongly connected to treatment delay as race.

"Our study found that Black women experienced delays in both treatment initiation and duration more often than white women. Even among women with low socioeconomic status, we still saw fewer delays among white women, underscoring the disparate experience of Black women, who appear to experience unique barriers," said Emerson, the paper's first author and postdoctoral fellow at UNC Lineberger and UNC Gillings.

Although they have a similar risk of developing breast cancer, Black women are 42% more likely than white women to die from the disease. Among women younger than 45, the mortality rate for black women is more than double that of white women.

The researchers analyzed the course of care of 2,841 women enrolled in the Carolina Breast Cancer Study Phase III, which is part of a population-based study UNC Lineberger and UNC Gillings School of Global Public Health launched in 1993 to investigate how the causes, treatments, and long-term outcomes of breast cancer differ between Black and white women. The women included in the new analysis were between 24 and 74 years of age at time of diagnosis, had stage 1, 2 or 3 breast cancer, and approximately half were Black.

The study used latent class analysis to group women according to a wide range of factors related to socioeconomic status, barriers to accessing care, and treatments and other patient factors that contribute to racial disparities. This aggregation allowed the investigators to consider how aggregated factors that may work together to define health care experiences.

"Describing and studying the complex set of factors that influence women's health care experience is a challenge, but this approach helps develop a more complex understanding," said Troester, the study's senior author and professor of epidemiology at the UNC Gillings and professor of pathology and lab medicine at UNC School of Medicine. "We observed that the duration of treatment was a particular sensitive indicator of access. This suggests that in addition to helping patients start treatment on time, we also have to work toward improving access so treatment doesn't drag on."
In addition to Troester and Emerson, the paper's other authors are Yvonne Golightly, PhD, and Alison Aiello, PhD, UNC Gillings; Katherine Reeder-Hayes, MD, and Ugwuji Maduekwe, MD, UNC Lineberger; Xiaming Tan, PhD, and Andrew Olshan, PhD, UNC Lineberger and UNC Gillings; and Marian Johnson-Thompson, PhD, Susan G. Komen Advocate in Science Steering Committee.

UNC Lineberger Comprehensive Cancer Center

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to